Biopharma's stock market winners of 2022 revealed
Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.
Big caps bounce back for biopharma
Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.
An annus horribilis for medtech flotations
Bausch & Lomb saves 2022's medtech IPO scene from washout as markets close for new entrants.
Biopharma’s venture year ends with another dip
Last year saw plenty of cash deployed, but with sums shrinking each quarter the stage is set for further retrenchment.
Biopharma’s bolt-on bonanza is set to continue
With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?
Amgen saves biopharma’s buyout year
December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.
JP Morgan 2023 – day one sees buyers make the most of straitened times
Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.
